ArticleAlzheimer's research & therapy2016
Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs.
Article in Alzheimer's research & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 24 citations in OpenAlex.
- Parkinsonian signs and cognitive trajectories in older adults: a population-based longitudinal study.Age and ageing · 2026Article
- Analyzing the 'Bradykinesia Complex' in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Predictive potential of circular walking in prodromal Parkinson's disease.Journal of Parkinson's disease · 2025Article
- Clinical and functional correlates of parkinsonism in a population-based sample of individuals aged 75 + : the Pietà study.BMC neurology · 2023Article
- Gait Analysis of Old Individuals with Mild Parkinsonian Signs and Those Individuals' Gait Performance Benefits Little from Levodopa.Risk management and healthcare policy · 2021Article
- Total Daily Physical Activity and the Risk of Parkinsonism in Community-Dwelling Older Adults.The journals of gerontology. Series A, Biological sciences and medical sciences · 2020Article
- Plasma amyloid-β levels, cerebral atrophy and risk of dementia: a population-based study.Alzheimer's research & therapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMild parkinsonian signs (MPS) are common in older people and are associated with an increased risk of different neurodegenerative diseases. This study prospectively evaluates the longitudinal course of cognitive performance in older individuals with MPS.
methodsFrom the TREND study, 480 individuals neurologically healthy at baseline, aged between 50 and 80 years, with complete follow-up data for three assessments within a mean of 43.8 months, were included in this analysis. Participants underwent a detailed cognitive test battery, evaluation of prodromal markers for neurodegenerative diseases and history of vascular diseases at each study visit. In addition, plasma levels of amyloid-beta (Aβ)
resultsIn 52 (11 %) of the 480 participants, MPS could be detected at baseline. These individuals had cognitive deficits significantly more often compared with controls at each time point and their cognitive performance showed a steeper decline during follow-up. In addition, their levels of plasma Aβ
conclusionsThis longitudinal study shows that MPS are associated with cognitive decline and decrease in plasma Aβ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.